CLAIMS

1. A thrombopoietin receptor activator represented by the formula (1)



(1)

[wherein each of R^1 and R^3 is independently a hydrogen atom, SO_3H, a C_{1-6} alkyl group, a C_{1-6} alkylcarbonyl group or a C_{6-18} arylcarbonyl group (C_{1-6} alkyl group, C_{1-6} alkylcarbonyl group and C_{6-18} arylcarbonyl group may be optionally substituted with a halogen atom, a hydroxyl group, a C_{2-6} alkenyl group, a C_{1-6} alkoxy group, a C_{1-6} alkoxycarbonyl group, a C_{6-18} aryl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-furanyl group, a 3-furanyl group, a 2-thienyl group, a 3-thienyl group (C_{6-18} aryl group, 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, 2-furanyl group, 3-furanyl group, 2-thienyl group and 3-thienyl group may be optionally substituted with a halogen atom or a C_{1-6} alkyl group) or NR^9R^{10} (wherein each of R^9 and R^{10} is independently a hydrogen atom or a C_{1-6} alkyl group (C_{1-6} alkyl group may be optionally substituted with a C_{6-18} aryl group) or R^9 and R^{10} mean, together with each other, $-(CH_2)_nX(CH_2)_m-$ (wherein X is $CR^{11}R^{12}$ (wherein each of R^{11} and R^{12} is independently a

hydrogen atom or a C_{1-6} alkyl group (the C_{1-6} alkyl group may be optionally substituted with a C_{6-18} aryl group)), NR^{13} (wherein R^{13} is a hydrogen atom or a C_{1-6} alkyl group (the C_{1-6} alkyl group may be optionally substituted with a C_{6-18} aryl group)), O or S, n is 1, 2 or 3, and m is 1, 2 or 3, provided that n+m is 3, 4 or 5))), and each of R^2, R^4 and R^a is independently a hydrogen atom, a hydroxyl group or a C_{1-6} alkoxy group].

2. The thrombopoietin receptor activator according to Claim 1, wherein each of R^1 and R^3 is independently a hydrogen atom, SO_3H, a C_{1-6} alkyl group, a C_{1-6} alkylcarbonyl group or a C_{6-18} arylcarbonyl group (the C_{1-6} alkyl group, the C_{1-6} alkylcarbonyl group and the C_{6-18} arylcarbonyl group may be optionally substituted with a hydroxyl group).

3. The thrombopoietin receptor activator according to Claim 1, wherein each of R^1 and R^3 is independently a hydrogen atom, SO_3H, a C_{1-6} alkyl group, a C_{1-6} alkylcarbonyl group or a C_{6-18} arylcarbonyl group (the C_{1-6} alkyl group, the C_{1-6} alkylcarbonyl group and the C_{6-18} arylcarbonyl group may be optionally substituted with NR^9R^{10} (wherein each of R^9 and R^{10} is independently a hydrogen atom or a C_{1-6} alkyl group (the C_{1-6} alkyl group may be optionally substituted with a C_{6-18} aryl group) or R^9 and R^{10} mean, together with each other, $-(CH_2)_nX(CH_2)_m-$ (wherein X is $CR^{11}R^{12}$ (wherein each of R^{11} and R^{12} is independently a hydrogen atom or a C_{1-6} alkyl group (the

C_{1-6} alkyl group may be optionally substituted with a C_{6-18} aryl group)), NR^{13} (wherein R^{13} is a hydrogen atom or a C_{1-6} alkyl group (the C_{1-6} alkyl group may be optionally substituted with a C_{6-18} aryl group)), O or S, n is 1, 2 or 3, and m is 1, 2 or 3, provided that n+m is 3, 4 or 5))).

4. The thrombopoietin receptor activator according to Claim 1, wherein each of R^1 and R^3 is independently a hydrogen atom or a C_{1-6} alkyl group.

5. the thrombopoietin receptor activator according to Claim 4, wherein each of R^1 and R^3 is independently a hydrogen atom or a methyl group, and each of R^2 and R^4 is independently a hydrogen atom, a hydroxyl group or a methoxy group.

6. The thrombopoietin receptor activator according to Claim 1, Claim 2, Claim 3, Claim 4 or Claim 5, wherein R^2 is a hydrogen atom.

7. The thrombopoietin receptor activator according to Claim 6, wherein each of R^4 and R^a is independently a hydrogen atom or a methoxy group.

8. A preventive, therapeutic or improving agent against which activation of the thrombopoietin receptor is effective, which contains the thrombopoietin receptor activator according to Claim 1, or a prodrug, pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

9. A platelet increasing agent containing the

thrombopoietin receptor activator according to Claim 1, or a prodrug, pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

10. A platelet increasing agent containing the thrombopoietin receptor activator according to Claim 2, or a prodrug, pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

11. A platelet increasing agent containing the thrombopoietin receptor activator according to Claim 3, or a prodrug, pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

12. A platelet increasing agent containing the thrombopoietin receptor activator according to Claim 4, or a prodrug, pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

13. A platelet increasing agent containing the thrombopoietin receptor activator according to Claim 5, or a prodrug, pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

14. A platelet increasing agent containing the thrombopoietin receptor activator according to Claim 6, or a prodrug, pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

15. A platelet increasing agent containing the thrombopoietin receptor activator according to Claim 7 or a prodrug, pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

16. A process for producing a compound represented by the formula (2), which comprises incubating a microorganism belonging to the Basipetospora genus and isolating the compound from the culture medium



(2)

(wherein each of R^5 and R^7 is independently a hydrogen atom or a methyl group, and each of R^6, R^8 and R^b is independently a hydrogen atom, a hydroxyl group or a methoxy group).

17. The process according to Claim 16, wherein the microorganism is Basipetospora sp.

18. Basipetospora sp. strain No. 1142 which is deposited under accession number FERM P-18940.

19. A compound represented by the formula (3).



(3)